ADVANCE CAPACITY: New Medication May Help Pulmonary Hypertension Patients Exercise


Trial Objective

A clinical trial called ADVANCE CAPACITY seeks to understand if an investigational medication called ralinepag will help people with pulmonary arterial hypertension (PAH) improve their ability to exercise. Participants will be randomly assigned ralinepag or a placebo, an inactive substance that looks like the investigational medication. During clinic visits, participants may be given a physical exam, provide a blood sample, complete a questionnaire, and/or receive an electrocardiogram, or EKG.  Participants' ability to exercise will be assessed using a stationary bike.


Active Clinical Trials Currently Recruiting

Who Can Participate

Patients diagnosed with pulmonary arterial hypertension

Age: 18+    Gender: Any Gender

Estimated Time Commitment

Up to 8 visits over 28 weeks

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jennifer Underwood

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

United Therapeutics

Principal Investigators


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: